Explore the most recent data on the drug situation in Europe provided by the EU Member States. These datasets underpin the analysis presented in the agency's work. Most data may be viewed interactively on screen and downloaded in Excel format.
We work closely with the 27 EU Member States plus Norway and Türkiye, candidates and potential candidates to the EU, the European Neighbourhood Policy countries and other third countries.
We have developed a systemic approach that brings together the human networks, processes and scientific tools necessary for collecting, analysing and reporting on the many aspects of the European drugs phenomenon.
Mounjaro (tirzepatide): The Newest Diabetes And Obesity Medication (explanation And Overview) How Do Ozempic Work
Location
Lisbon
Publication date
Reference
News release
In United States Publish Post Time: 2025-07-19
Tirzepatide (brand name: Mounjaro) is the newest injectable medication for the treatment of type II diabetes and obesity. Mounjaro was recently approved for diabetes and is awaiting FDA approval for the primary treatment of obesity. Based on the results of the SURMOUNT trial, tirzepatide will likely be the most effective obesity medication EVER. This once per week injection produced an average weight loss of nearly 21% of body weight at 72 weeks.
In this video, Dr. Christopher McGowan, MD, MSCR, of True You Weight Loss, explains how tirzepatide (Mounjaro) works, common side effects, expectations, and a comparison to other weight loss medications.
#obesitytreatment #obesity #weightloss #weightlosstreatment
Mounjaro (tirzepatide): The Newest Diabetes And Obesity Medication (explanation And Overview) For Country: United States. City: Bakersfield, Houston, Oceanside, Washington, Winston-Salem
To schedule interviews, obtain informed comment, request written contributions or receive the latest news on the agency, please contact our media relations sector:
Kathy Robertson
Principal manager
Media relations and corporate communication